FAP inhibitors: are we really using the best method to evaluate the residence time?

Fibroblast activation protein inhibitors (FAPIs) have revolutionized molecular imaging, particularly with the development of PET tracers targeting the tumor microenvironment. Developing high-throughput and reproducible RT assays will expand the range of candidate molecules for screening, ultimately increasing the likelihood of successful therapeutic breakthroughs in the FAPI field. Enhanced collaboration between academic researchers, industry and regulatory bodies will also be crucial to integrate RT measurement as a standard component of drug discovery workflows.